Literature DB >> 28300475

Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1.

Dong Li1, Jianqing Xu1, Zhuozhi Wang1, Zhen Gong2, Jieying Liu1, Yong Zheng1, Jian Li2, Jing Li1.   

Abstract

Of the inhibitory checkpoints in the immune system, programmed death 1 (PD-1) is one of the most promising targets for cancer immunotherapy. The anti-PD-1 antibodies currently approved for clinical use or under development bind to human PD-1 (hPD-1), but not murine PD-1. To facilitate studies in murine models, we developed a functional antibody against both human and murine PD-1, and compared the epitopes of such antibody to a counterpart that only bound to hPD-1. To quickly identify the epitopes of the 2 antibodies, we used alanine scanning and mammalian cell expression cassette. The epitope identification was based on PD-1-binding ELISA and supported by affinity ranking of surface plasmon resonance results. The hPD-1 epitopes of the 2 functional antibodies were also compared with the binding region on hPD-1 that is responsible for PD-L1 interaction. In silico modeling were conducted to explain the different binding modes of the 2 antibodies, suggesting a potential mechanism of the antibody cross-species binding.

Entities:  

Keywords:  Cross-species binding; Programmed death 1 (PD-1); epitope mapping; functional antibody; modeling

Mesh:

Substances:

Year:  2017        PMID: 28300475      PMCID: PMC5419084          DOI: 10.1080/19420862.2017.1296612

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  21 in total

1.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 2.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

3.  The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.

Authors:  David Yin-Wei Lin; Yoshimasa Tanaka; Masashi Iwasaki; Apostolos G Gittis; Hua-Poo Su; Bunzo Mikami; Taku Okazaki; Tasuku Honjo; Nagahiro Minato; David N Garboczi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-14       Impact factor: 11.205

4.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Authors:  Krzysztof M Zak; Radoslaw Kitel; Sara Przetocka; Przemyslaw Golik; Katarzyna Guzik; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Structure       Date:  2015-10-22       Impact factor: 5.006

5.  Structure and interactions of the human programmed cell death 1 receptor.

Authors:  Xiaoxiao Cheng; Vaclav Veverka; Anand Radhakrishnan; Lorna C Waters; Frederick W Muskett; Sara H Morgan; Jiandong Huo; Chao Yu; Edward J Evans; Alasdair J Leslie; Meryn Griffiths; Colin Stubberfield; Robert Griffin; Alistair J Henry; Andreas Jansson; John E Ladbury; Shinji Ikemizu; Mark D Carr; Simon J Davis
Journal:  J Biol Chem       Date:  2013-02-15       Impact factor: 5.157

6.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.

Authors:  Michael A Morse; Jennifer Garst; Takuya Osada; Shubi Khan; Amy Hobeika; Timothy M Clay; Nancy Valente; Revati Shreeniwas; Mary Ann Sutton; Alain Delcayre; Di-Hwei Hsu; Jean-Bernard Le Pecq; H Kim Lyerly
Journal:  J Transl Med       Date:  2005-02-21       Impact factor: 5.531

Review 7.  Immunotherapeutic approaches to ovarian cancer treatment.

Authors:  Cariad Chester; Oliver Dorigo; Jonathan S Berek; Holbrook Kohrt
Journal:  J Immunother Cancer       Date:  2015-03-24       Impact factor: 13.751

8.  Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.

Authors:  Madison Black; Ivraym B Barsoum; Peter Truesdell; Tiziana Cotechini; Shannyn K Macdonald-Goodfellow; Margaret Petroff; D Robert Siemens; Madhuri Koti; Andrew W B Craig; Charles H Graham
Journal:  Oncotarget       Date:  2016-03-01

Review 9.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Authors:  Li Shi; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2013-09-30       Impact factor: 17.388

10.  Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.

Authors:  Mark J Selby; John J Engelhardt; Robert J Johnston; Li-Sheng Lu; Minhua Han; Kent Thudium; Dapeng Yao; Michael Quigley; Jose Valle; Changyu Wang; Bing Chen; Pina M Cardarelli; Diann Blanset; Alan J Korman
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

View more
  4 in total

1.  TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.

Authors:  Daniel R Principe; Alex Park; Matthew J Dorman; Sandeep Kumar; Navin Viswakarma; Jonathan Rubin; Carolina Torres; Ronald McKinney; Hidayatullah G Munshi; Paul J Grippo; Ajay Rana
Journal:  Mol Cancer Ther       Date:  2018-12-26       Impact factor: 6.009

2.  A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope.

Authors:  Dong Li; Jing Li; Huanyu Chu; Zhuozhi Wang
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

3.  Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model.

Authors:  Jang-Gi Choi; Young Soo Kim; Ji Hye Kim; Tae In Kim; Wei Li; Tae Woo Oh; Chang Hyun Jeon; Su Jin Kim; Hwan-Suck Chung
Journal:  Front Immunol       Date:  2020-11-05       Impact factor: 7.561

4.  Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds.

Authors:  Wei Li; Tae In Kim; Ji Hye Kim; Hwan-Suck Chung
Journal:  Molecules       Date:  2019-11-09       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.